Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCH | P24723 | 20/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 20/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 20/20 | 1.00 |
| ▸ | PRKCA | P17252 | 19/20 | 1.00 |
| ▸ | PRKCB | P05771 | 18/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 17/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.69 |
| ▸ | PIM1 | P11309 | 3/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.69 |
| ▸ | MARK3 | P27448 | 2/20 | 0.69 |
| ▸ | LTK | P29376 | 2/20 | 0.69 |
| ▸ | GRK5 | P34947 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | GSK3A | P49840 | 2/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 2/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.69 |
| ▸ | MST1R | Q04912 | 2/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4377883 | 0.86 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL857150 | 0.84 | PRKCQ (0.72) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL22410995 | 0.83 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL4543351 | 0.82 | PRKCB (0.69) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29364923 | 0.82 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL2500835 | 0.82 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| Sotrastaurin SCHEMBL29526075 | 0.82 | PRKCH (1.00) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL990670 | 0.81 | PRKCH (0.71) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL992515 | 0.80 | PRKCH (0.69) | PRKCHPRKCQPRKCDPRKCAPRKCB | |
| SCHEMBL4905416 | 0.79 | PRKCH (0.76) | PRKCHPRKCQPRKCDPRKCAPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337527-B1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | claimed |
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| US-20070184061-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-08-09 | — | — | US | disclosed |
| US-20070184061-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-08-09 | — | — | US | disclosed |
| US-20070155817-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-07-05 | — | — | US | disclosed |
| US-20070155817-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-07-05 | — | — | US | disclosed |
| US-7220774-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-05-22 | — | — | US | disclosed |
| US-7220774-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318463-A1 | Indolylmaleimide Derivatives | NFATC1, INMT, IDO1 | PRKCH 1941/4885PRKCQ 1600/4885PRKCD 1485/4885 |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | PRKCH 3333/4885PRKCQ 2637/4885PRKCD 2636/4885 |
| US-20070155817-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | PRKCH 1941/4885PRKCQ 1600/4885PRKCD 1485/4885 |
| US-20070184061-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | PRKCH 1941/4885PRKCQ 1600/4885PRKCD 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.